Prodromes of Menstrual Staphylococcal Toxic Shock

NCT06124599 · tracked via the Priya Life Science France tracker

Sponsor

Hospices Civils de Lyon

Phase

Observational

Started

2021-12-21

Last updated

2024-12-06

Condition(s) studied

Toxic Shock Syndrome Staphylococcal

Investigational drug(s) / intervention(s)

Identification of symptoms of menstrual staphylococcal toxic shock in last three menstrual periodIdentification of symptoms of menstrual in control patient in the last three menstrual period

Identification of symptoms of menstrual staphylococcal toxic shock in last three menstrual period: questionnaire including : fever felt or measured; chills; malaise or feeling of malaise (dizziness when standing up); unusual fatigue; headache; confusion, disorientation; nausea; vomiting; diarrhea; abdominal pain; muscle pain, aches; sore throat or pain when swallowing; red tongue or mouth ulceration; skin rashes (redness, patches...); other

Identification of symptoms of menstrual in control patient in the last three menstrual period: questionnaire including : fever felt or measured; chills; malaise or feeling of malaise (dizziness when standing up); unusual fatigue; headache; confusion, disorientation; nausea; vomiting; diarrhea; abdominal pain; muscle pain, aches; sore throat or pain when swallowing; red tongue or mouth ulceration; skin rashes (redness, patches...); other...

Study summary

Menstrual staphylococcal toxic shock is a rare but severe disease, requiring intensive care in over 80% of cases. Menstrual staphylococcal toxic shock develops during the peri-menstrual period, in healthy young women colonized by a vaginal strain of Staphylococcus aureus secreting the Toxic shock syndrome toxin 1 (TSST-1) and not immune to it, in a favorable environment, i.e. wearing intravaginal menstrual protection (tampon, menstrual cup).

The rarity of the syndrome, its polymorphous clinical presentation and the absence of a totally specific biological examination make menstrual staphylococcal toxic shock a difficult pathology to diagnose. The reference clinical criteria correspond to the advanced picture of multivisceral failure, making it possible to classify cases a posteriori, but contribute to diagnostic delay and lack sensitivity.

Patient accounts suggest the presence of symptoms in the days preceding the development of toxic shock, and also during previous menstrual cycles.

The identification of prodromal symptoms could enable earlier management of menstrual staphylococcal toxic shock by removal of intra-vaginal sanitary protection, the main risk factor, before the disease becomes permanently established and requires intensive care.

Eligibility

Sex

FEMALE

Min age

13 Years

Max age

30 Years

Healthy volunteers

Accepted

Inclusion Criteria : +Case inclusion criteria: * Women between 13 and 30 years old inclusive * Clinical diagnosis of staphylococcal toxic shock syndrome: "confirmed" or "probable" according to Center Disease Control (CDC) criteria: The 5 CDC clinical criteria for menstrual Staphylococcal Toxic Shock are: * a fever above 39°C, * arterial hypotension, * generalized scarlatiniform erythroderma * intense peeling of the palms or soles of the feet 7 to 14 days later, * and systemic manifestations (at least three): * Digestive: vomiting, diarrhea * Muscular: myalgia, increase in serum creatine phosphokinase * Hyperemia of the vaginal, oropharyngeal and conjunctival mucous membranes * Renal: hyperuricemia, hypercreatininemia, leukocyturia without urinary infection, * Hepatic: increase in transaminases * Hematological: thrombocytopenia (\< 100,000 platelets/mm3) * Neurological: apart from episodes of fever or hypotension such as disorientation or altered consciousness. In the presence of 4 criteria, the case is considered probable and 5 criteria as confirmed case. * Detection of S. aureus strain carrying Toxic shock syndrome toxin-1 (TSST1) on vaginal samples. * Onset of symptoms ≤ 72 hours before the start of menstruation and ≥ 72 hours after the end of menstruation. * Use during the last 3 cycles of vaginal protection: tampon or menstrual cup. +Control inclusion criteria: * Women between 13 and 30 years old inclusive * Presence of menstruation * Use of intimate periodic protection, tampon or menstrual cup, during the last 3 periods * No history of toxic menstrual shock Exclusion Criteria: * Non-menstruating women * Women protected by law * Women (or relatives) who oppose the study

Primary outcome measure(s)

Women with No history of menstrual toxic shock for controls — in the week following the last menstrual period
A single collection of information through a questionnaire delivered to the last menstrual period
Patient with Menstrual Staphylococcal Toxic Shock (STC) — in the week following onset Staphylococcal Toxic Shock
A single collection of information through a questionnaire delivered as close as possible to the occurrence of the STC

Trial sites (1)

Facility	City	Region	Status
Hopital Nord Croix Rousse	Lyon	France	Recruiting

More Hospices Civils de Lyon trials in France

Non-invasive Personalized Transcranial Cortical Neurostimulation for Pain Relief Recruiting

Validation of the French Version of the New Mobility Score (NMS) Recruiting

Burosumab and 1-25 (OH) Vitamin D on Human Osteoblasts Recruiting

Impact of Mental Health First Aid-trained Peers on the Mental Well-being of First-year Medical Residents. Active, not recruiting

Psychological Support Interventions for Women With Endometriosis (ENDOPSY) Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06124599 on ClinicalTrials.gov ↗ ← All trials in France